Evidence Hub

Acute Hypersensitivity Reaction With Maculopapular Exanthem and Angio-Oedema Following Low Dose Amitriptyline for Migraine Prophylaxis: A Case Report

B. P. Singh, Anna Javed, Sartaj Hussain, Ritesh Kumar

Cureus, 2025

Abstract

We report a case of a 34‑year‑old woman who developed a generalized maculopapular rash accompanied by urticaria‑like pruritus, angio‑oedema, and mild dyspnoea. The reaction occurred approximately one hour after ingestion of her routine 10 mg dose of amitriptyline, following four weeks of therapy for migraine prophylaxis. Laboratory studies showed elevated erythrocyte sedimentation rate (ESR) and CRP with normal eosinophil counts and negative viral serology; imaging was unremarkable. Causality, assessed with the World Health Organization-Uppsala Monitoring Centre system (WHO‑UMC) and Naranjo algorithms, was “probable.” Prompt cessation of the medication, H1 receptor antagonism combined with leukotriene‑receptor blockade, and supportive treatment resulted in complete recovery by day eight, with no recurrence observed at the three-month follow-up. This case expands the limited literature on tricyclic antidepressant (TCA)-induced hypersensitivity and emphasizes the importance of timely recognition, discontinuation, and pharmacovigilance reporting for patient safety.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free